Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
The Clinical Picture

Exanthem and enanthem with fever and dyspnea

George D. Liatsos, MD, PhD and Emmanouil Koullias, MD
Cleveland Clinic Journal of Medicine December 2021, 88 (12) 653-655; DOI: https://doi.org/10.3949/ccjm.88a.21047
George D. Liatsos
Staff Consultant A, Department of Internal Medicine, “Hippokration” General Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Emmanouil Koullias
Internist, Department of Internal Medicine, “Hippokration” General Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 49-year-old woman presented with a 5-day history of high fever, productive cough, mild dyspnea, malaise, generalized myalgias, and conjunctivitis. Hours before admission she developed a maculopapular rash. She had been diagnosed 2 years earlier with decompensated liver cirrhosis due to autoimmune hepatitis–primary biliary cholangitis overlap syndrome and was currently being treated with prednisolone, azathioprine, and ursodeoxycholic acid.

WORKUP AND HOSPITAL COURSE

On examination, her temperature was 38.3°C (100.9°F), heart rate 92 beats per minute, blood pressure 100/68 mm Hg, respiratory rate 24 breaths per minute, and oxygen saturation 92% on ambient air. An erythematous, maculopapular, blanching rash was noted on the face and trunk (Figure 1), as well as enanthem on the buccal mucosa opposite the molars (Figure 2). Auscultation detected basilar fine crackles in both lungs. A firm liver was palpable 2 to 3 fingers below the right costal margin without tenderness. The rest of the physical examination was unremarkable.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Erythematous, maculopapular, blanching rash on the trunk.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Koplik spots (black arrows), whitish, grayish, or bluish elevations of 1 to 3 mm with an erythematous base on the buccal mucosa opposite the molars.

Laboratory testing revealed leukopenia, thrombocytopenia, and increased serum levels of aspartate aminotransferase, lactate dehydrogenase, creatine kinase, gamma-glutamyl transferase, and total bilirubin.

The patient’s dyspnea deteriorated significantly over the next 2 days, accompanied by high fever, with temperatures of 39.6°C to 40.5°C (103.3°F to 104.9°F). The initial findings on auscultation worsened and included diffuse bilateral crackles. Arterial blood gas analysis revealed hypoxemia (Pao2 59 mm Hg, Pco2 27 mm Hg), while she was breathing 3 L of oxygen per minute by nasal cannula.

Computed tomography of the lungs revealed bilateral infiltrates and ground-glass opacities in the upper lobes (Figure 3). Serologic testing by enzyme-linked immunosorbent assay confirmed the presence of positive immunoglobulin M antibodies against measles virus. She was treated with 40% oxygen through a face mask, intravenous levofloxacin, and oral ribavirin. As the enanthem (Koplik spots) prevented the patient from consuming adequate fluids and food, supportive care was provided including D/W 5% daily by intravenous infusion. The patient was discharged 1 week later in good condition, and at a follow-up visit 1 month after discharge, she was asymptomatic.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Computed tomography of the lungs revealed bilateral infiltrates (arrows) and ground-glass opacities (arrowheads) mainly in the upper lobes.

DISCUSSION

Measles is a highly contagious viral illness with a 90% transmission rate to susceptible individuals. The majority of deaths are from pneumonitis or encephalitis, while the most common complication is diarrhea. During the 2018 measles outbreak in Europe, tens of thousands of cases were reported, with two-thirds of patients requiring hospitalization.1

The incubation period for measles is 8 to 12 days2 and begins after virus entry via respiratory mucosa or conjuctivae. The virus replicates locally, spreads to regional lymphatic tissues, and is then thought to be disseminated to other reticuloendothelial sites through the blood stream (“primary viremia”).3 The prodromal phase is defined by the appearance of symptoms that typically include fever, malaise, and anorexia, followed by conjunctivitis that may be accompanied by lacrimation or photophobia, coryza, and cough.2,3 Respiratory symptoms result from mucosal inflammation from viral infection of epithelial cells.

Prodromal symptoms typically intensify a few days before exanthem appears. Around 48 hours before the onset of exanthem, patients may develop enanthem characterized by Koplik spots, whitish, grayish, or bluish elevations of 1 to 3 mm with an erythematous base, typically on the buccal mucosa opposite the molars. Koplik spots are considered pathognomonic for measles.3 They may spread to cover the buccal and labial mucosa and the hard and soft palate.

Although a safe and effective measles vaccine was developed in 1963 and was eventually included in the trivalent measles-mumps-rubella vaccine in 1981 in the Greek National Vaccination Program, this patient had not been vaccinated against measles as a child or as an adult.

CLINICAL DIFFERENTIAL DIAGNOSIS

Once exanthem appears, the differential diagnosis for measles includes varicella, roseola (human herpesvirus 6 and 7), enteroviruses (coxsackievirus A9 and B5), erythema infectiosum (parvovirus B19), rubella, infectious mononucleosis, Epstein-Barr virus (especially during amoxicillin treatment), and group A streptococcal infection.

If dyspnea develops, the differential diagnosis may encompass Rocky Mountain spotted fever, meningococcemia, and Mycoplasma pneumoniae-induced rash and mucositis. In immunocompromised individuals like this patient, the differential diagnosis also includes Candida albicans mucositis with subsequent fungemia and pneumonia, and herpes simplex virus type 1 infection with viremia and endorgan disease.

The presence of Koplik spots along with the symptoms typical for viral infection makes measles the most likely diagnosis even before the development of exanthem.

SUPPORTIVE TREATMENT IS THE STANDARD

The mainstay of measles treatment is supportive. Treatment of bacterial superinfections such as bacterial pneumonia and otitis, as well as seizures and respiratory failure, may also be necessary. Administration of vitamin A to children with measles is associated with decreased morbidity and mortality.4

Early initiation of ribavirin treatment—within the first 5 days of disease onset—seems more effective than later in the disease course.5 Given the high risk of measles-associated mortality in immunosuppressed individuals6 and the absence of treatment guidelines, some authors have recommended ribavirin treatment in patients with measles complications (mostly pneumonitis and encephalitis).5

In a prospective study of 100 patients with measles, half were assigned to treatment with ribavirin and supportive therapy, and the other 50 patients received only supportive therapy. Those receiving ribavirin had earlier resolution of fever and constitutional symptoms and fewer complications than those receiving only supportive care.7

The optimal duration of ribavirin therapy is not known, but 5 to 7 days may be reasonable except for severely immunosuppressed patients, who may require 2 to 3 weeks of treatment.8

TEACHING POINT

In patients with short-term high fevers and symptoms of viral infection (eg, malaise, generalized myalgias, conjunctivitis) but no maculopapular rash, a thorough inspection of the buccal cavity for Koplik spots will allow for a timely diagnosis of measles and for prompt administration of ribavirin if dyspnea or other complications develop.4

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. World Health Organization (WHO)
    . Measles. https://www.who.int/news-room/fact-sheets/detail/measles. Accessed November 3, 2021.
  2. ↵
    1. Porter A,
    2. Goldfarb J
    . Measles: a dangerous vaccine-preventable disease returns. Cleve Clin J Med 2019; 86(6):393–398. doi:10.3949/ccjm.86a.19065
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Strebel PM,
    2. Orenstein WA
    . Measles. N Engl J Med 2019; 381(4):349–357. doi:10.1056/NEJMcp1905181
    OpenUrlCrossRefPubMed
  4. ↵
    1. Huiming Y,
    2. Chaomin W,
    3. Meng M
    . Vitamin A for treating measles in children. Cochrane Database Syst Rev 2005; 2005(4):CD001479. doi:10.1002/14651858.CD001479.pub3
    OpenUrlCrossRef
  5. ↵
    1. Roy Moulik N,
    2. Kumar A,
    3. Jain A,
    4. Jain P
    . Measles outbreak in a pediatric oncology unit and the role of ribavirin in prevention of complications and containment of the outbreak. Pediatr Blood Cancer 2013; 60(10):E122–E124. doi:10.1002/pbc.24575
    OpenUrlCrossRef
  6. ↵
    1. Misin A,
    2. Antonello RM,
    3. Di Bella S, et al
    . Measles: an overview of a re-emerging disease in children and immunocompromised patients. Microorganisms 2020; 8(2):276. Published 2020 Feb 18. doi:10.3390/microorganisms8020276
    OpenUrlCrossRef
  7. ↵
    1. Pal G
    . Effects of ribavirin on measles. J Indian Med Assoc 2011; 109(9):666–667. pmid:22480102
    OpenUrlPubMed
  8. ↵
    1. Liatsos GD
    . Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19):5135–5178. doi:10.12998/wjcc.v9.i19.5135
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (12)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 12
1 Dec 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exanthem and enanthem with fever and dyspnea
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Exanthem and enanthem with fever and dyspnea
George D. Liatsos, Emmanouil Koullias
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 653-655; DOI: 10.3949/ccjm.88a.21047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Exanthem and enanthem with fever and dyspnea
George D. Liatsos, Emmanouil Koullias
Cleveland Clinic Journal of Medicine Dec 2021, 88 (12) 653-655; DOI: 10.3949/ccjm.88a.21047
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • WORKUP AND HOSPITAL COURSE
    • DISCUSSION
    • CLINICAL DIFFERENTIAL DIAGNOSIS
    • SUPPORTIVE TREATMENT IS THE STANDARD
    • TEACHING POINT
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tinea incognito
  • Prolonged venous filling time and dependent rubor in a patient with peripheral artery disease
  • Sarcoidosis with diffuse purplish erythematous plaques on the hands
Show more The Clinical Picture

Similar Articles

Subjects

  • Dermatology
  • Emergency Medicine
  • Imaging
  • Infectious Diseases
  • Pulmonology
  • Rheumatology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire